guest ::
| Home > Publications Database > LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease. > print |
| Home > Publications Database > LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease. > print |
| 001 | 164913 | ||
| 005 | 20230915090559.0 | ||
| 024 | 7 | _ | |a 10.1038/s41531-022-00354-3 |2 doi |
| 024 | 7 | _ | |a pmid:35853899 |2 pmid |
| 024 | 7 | _ | |a pmc:PMC9296523 |2 pmc |
| 024 | 7 | _ | |a altmetric:132819564 |2 altmetric |
| 037 | _ | _ | |a DZNE-2022-01324 |
| 041 | _ | _ | |a English |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Kedariti, Maria |0 0000-0002-6311-5273 |b 0 |
| 245 | _ | _ | |a LRRK2 kinase activity regulates GCase level and enzymatic activity differently depending on cell type in Parkinson's disease. |
| 260 | _ | _ | |a London [u.a.] |c 2022 |b Nature Publ. Group |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1659439081_5125 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a CC BY |
| 520 | _ | _ | |a Leucine-rich repeat kinase 2 (LRRK2) is a kinase involved in different cellular functions, including autophagy, endolysosomal pathways, and immune function. Mutations in LRRK2 cause autosomal-dominant forms of Parkinson's disease (PD). Heterozygous mutations in GBA1, the gene encoding the lysosomal enzyme glucocerebrosidase (GCase), are the most common genetic risk factors for PD. Moreover, GCase function is altered in idiopathic PD and in other genetic forms of the disease. Recent work suggests that LRRK2 kinase activity can regulate GCase function. However, both a positive and a negative correlation have been described. To gain insights into the impact of LRRK2 on GCase, we performed a comprehensive analysis of GCase levels and activity in complementary LRRK2 models, including (i) LRRK2 G2019S knock in (GSKI) mice, (ii) peripheral blood mononuclear cell (PBMCs), plasma, and fibroblasts from PD patients carrying LRRK2 G2019S mutation, (iii) patient iPSCs-derived neurons; (iv) endogenous and overexpressed cell models. In some of these models we found a positive correlation between the activities of LRRK2 and GCase, which was further confirmed in cell lines with genetic and pharmacological manipulation of LRRK2 kinase activity. GCase protein level is reduced in GSKI brain tissues and in G2019S iPSCs-derived neurons, but increased in fibroblasts and PBMCs from patients, suggesting cell-type-specific effects. Overall, our study indicates that LRRK2 kinase activity affects both the levels and the catalytic activity of GCase in a cell-type-specific manner, with important implications in the context of therapeutic application of LRRK2 inhibitors in GBA1-linked and idiopathic PD. |
| 536 | _ | _ | |a 352 - Disease Mechanisms (POF4-352) |0 G:(DE-HGF)POF4-352 |c POF4-352 |f POF IV |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de |
| 700 | 1 | _ | |a Frattini, Emanuele |b 1 |
| 700 | 1 | _ | |a Baden, Pascale |0 P:(DE-2719)2811884 |b 2 |u dzne |
| 700 | 1 | _ | |a Cogo, Susanna |b 3 |
| 700 | 1 | _ | |a Civiero, Laura |0 0000-0002-5334-155X |b 4 |
| 700 | 1 | _ | |a Ziviani, Elena |b 5 |
| 700 | 1 | _ | |a Zilio, Gianluca |b 6 |
| 700 | 1 | _ | |a Bertoli, Federico |0 P:(DE-2719)9001762 |b 7 |u dzne |
| 700 | 1 | _ | |a Aureli, Massimo |b 8 |
| 700 | 1 | _ | |a Kaganovich, Alice |b 9 |
| 700 | 1 | _ | |a Cookson, Mark R |0 0000-0002-1058-3831 |b 10 |
| 700 | 1 | _ | |a Stefanis, Leonidas |0 0000-0003-3569-8990 |b 11 |
| 700 | 1 | _ | |a Surface, Matthew |0 0000-0002-4933-2618 |b 12 |
| 700 | 1 | _ | |a Deleidi, Michela |0 P:(DE-2719)2810385 |b 13 |u dzne |
| 700 | 1 | _ | |a Di Fonzo, Alessio |0 0000-0001-6478-026X |b 14 |
| 700 | 1 | _ | |a Alcalay, Roy N |b 15 |
| 700 | 1 | _ | |a Rideout, Hardy |b 16 |
| 700 | 1 | _ | |a Greggio, Elisa |0 0000-0002-8172-3598 |b 17 |
| 700 | 1 | _ | |a Plotegher, Nicoletta |0 0000-0001-7421-8705 |b 18 |
| 773 | _ | _ | |a 10.1038/s41531-022-00354-3 |g Vol. 8, no. 1, p. 92 |0 PERI:(DE-600)2819218-7 |p 92 |t npj Parkinson's Disease |v 8 |y 2022 |x 2373-8057 |
| 856 | 4 | _ | |y OpenAccess |u https://pub.dzne.de/record/164913/files/DZNE-2022-01324.pdf |
| 856 | 4 | _ | |y OpenAccess |x pdfa |u https://pub.dzne.de/record/164913/files/DZNE-2022-01324.pdf?subformat=pdfa |
| 909 | C | O | |o oai:pub.dzne.de:164913 |p openaire |p open_access |p VDB |p driver |p dnbdelivery |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 2 |6 P:(DE-2719)2811884 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 7 |6 P:(DE-2719)9001762 |
| 910 | 1 | _ | |a Deutsches Zentrum für Neurodegenerative Erkrankungen |0 I:(DE-588)1065079516 |k DZNE |b 13 |6 P:(DE-2719)2810385 |
| 913 | 1 | _ | |a DE-HGF |b Gesundheit |l Neurodegenerative Diseases |1 G:(DE-HGF)POF4-350 |0 G:(DE-HGF)POF4-352 |3 G:(DE-HGF)POF4 |2 G:(DE-HGF)POF4-300 |4 G:(DE-HGF)POF |v Disease Mechanisms |x 0 |
| 914 | 1 | _ | |y 2022 |
| 915 | _ | _ | |a Creative Commons Attribution CC BY (No Version) |0 LIC:(DE-HGF)CCBYNV |2 V:(DE-HGF) |b DOAJ |d 2020-09-03 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0160 |2 StatID |b Essential Science Indicators |d 2020-09-03 |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0113 |2 StatID |b Science Citation Index Expanded |d 2020-09-03 |
| 915 | _ | _ | |a Fees |0 StatID:(DE-HGF)0700 |2 StatID |d 2020-09-03 |
| 915 | _ | _ | |a OpenAccess |0 StatID:(DE-HGF)0510 |2 StatID |
| 915 | _ | _ | |a Article Processing Charges |0 StatID:(DE-HGF)0561 |2 StatID |d 2020-09-03 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b NPJ PARKINSONS DIS : 2021 |d 2023-03-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |d 2023-03-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |d 2023-03-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0501 |2 StatID |b DOAJ Seal |d 2021-10-13T14:34:28Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0500 |2 StatID |b DOAJ |d 2021-10-13T14:34:28Z |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b DOAJ : Blind peer review |d 2021-10-13T14:34:28Z |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |d 2023-03-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |d 2023-03-31 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |d 2023-03-31 |
| 915 | _ | _ | |a IF >= 5 |0 StatID:(DE-HGF)9905 |2 StatID |b NPJ PARKINSONS DIS : 2021 |d 2023-03-31 |
| 920 | 1 | _ | |0 I:(DE-2719)1210011 |k AG Deleidi |l Mitochondria and inflammation in neurodegeneration |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a UNRESTRICTED |
| 980 | _ | _ | |a I:(DE-2719)1210011 |
| 980 | 1 | _ | |a FullTexts |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|